Tufts Health Care Institute Program on
| |||
May 4-5, 2012
Overview and purpose of the meeting Developing an ideal analgesic:
the need now is greater than ever Keynote address: the historical drive for the search for the ideal analgesic Do we still need a better analgesic: public health, public policy, and ethical perspectives The origin and history of the National Institutes of Health/College on Problems of Drug Dependence (CPDD) medicines development program: focus on chemistry, lessons for the future Pre-clinical pharmacology approaches in the NIH Medicines Development Program and lessons for the future New approaches in the development of opioids and other analgesics New targets for opioids lacking
side-effects A Personal Perspective on Preclinical Drug Development Clinical characterization of compounds at the Addiction Research Center Clinical testing of analgesics: past, present and future The current strategy for developing strong non-addictive pain relievers in the pharmaceutical industry Recent progress in grassroots advocacy for addressing the opioid abuse problem NIH Pain Consortium and Translational Medicine Program The FDA ACTTION public-private partnership: what is the FDA doing to accelerate the development of better analgesics? Legislative update: current efforts to increase federal spending on pain research
| |||
©
2008 Tufts Health Care Institute •
Boston, MA 02111 •
(617) 636-1000 |
|||
The mission of the Tufts
Health Care Institute Program on Opioid Risk Management is to address challenges
in the development and utilization of opioid analgesics, by engaging a multidisciplinary
group of stakeholders focused on optimizing the benefits of opioid for pain management,
and minimizing their risks, including abuse and diversion.